New NCCN guidelines on prostate cancer are not an all-around success!

Alas, the latest revisions to the National Comprehensive Cancer Network (NCCN) guidelines on early detection of prostate cancer seem to have instigated more furore than they have clarity (although the original premise behind them may have been well intentioned). … READ MORE …

“Five golden rules” for prostate cancer screening and treatment today

In a very simple and straightforward article in European Urology, Vickers et al. have clearly laid out a series of five “golden rules” that, in their opinion, all physicians should be following today when they are testing men for risk of prostate cancer through the use of the PSA test. … READ MORE …

New prostate cancer “vaccine” in Phase II trial prior to ADT

According to a media release we saw this morning, a company called Madison Vaccines has started a Phase II clinical trial of a new form of immunotherapy for treatment of men with non-metastatic prostate cancer and rising PSA levels prior to any treatment with androgen deprivation therapy (ADT). … READ MORE …

Criteria for active surveillance are gradually improving

Being diagnosed with low-risk prostate cancer is a good reason to consider management under active surveillance (as opposed to immediate, early intervention) … but active surveillance won’t be right for every low-risk patient! … READ MORE …

Poor guidance from the AAFP, badly interpreted by the media

According to a recent recommendation from the American Academy of Family Physicians in association with the Choosing Wisely campaign. primary care physicians are being advised as follows: … READ MORE …

New prospective study supports baseline PSA testing for men in 40s

According to a newly published, prospective study in the Journal of Urology, a research team at the Mayo Clinic has confirmed prior reports (based on retrospective data) that a baseline PSA in men aged between 40 and 49 years can be used to categorize men into low and higher prostate cancer risk groups. … READ MORE …

Urologists’ and radiation oncologists’ opinions on use of PSA test to screen for prostate cancer

A new study has provided data on the opinions of a random sample of 1,366 radiation oncologists and urologists with regard to the appropriate role of the PSA test in screening for prostate cancer (since the recommendation of a D grade for this test as a screening mechanism by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

Dr. David Agus on CBS’s “Morning Rounds”

So the role of prostate cancer screening got discussed on the CBS television program “Morning Rounds” on Saturday, by Dr. David Agus (a well-known urologic oncologist) and others. The context was the recent data on the “overuse” of the PSA test in men of 75+ years of age. … READ MORE …

Cost and prevalence of PSA testing in Medicare patients > 70 years old

A recent article in Cancer has stimulated media coverage of the appropriate role of PSA testing in men of > 70 years of age and costs covered by Medicare for PSA tests in men over this age. … READ MORE …

From Amsterdam yesterday: European perspectives on the PSA screening issue

A report on the Medscape Oncology web site, published late yesterday, discusses two presentations given yesterday at the European Cancer Conference 2013, currently being held in Amsterdam. … READ MORE …

Appropriate use of the PSA test for assessing risk of prostate cancer

The following quotation is from the abstract of a recent review of the appropriate use of the PSA test in the assessment of risk for prostate cancer: … READ MORE …

New “six-point” statement about prostate cancer screening (redux)

Three weeks ago we mentioned a new six-point statement about PSA screening developed at a meeting in Melbourne, Australia. We would note that an updated set of information about this statement is now available on the BJU International web site. … READ MORE …

Flawed PSA test provides inaccurate results in Pennsylvania

We’ve said it before. We’ll say it again. And now there’s an even better reason to take the message seriously. … A single, slightly elevated PSA test result is rarely a good reason to rush off and get a prostate biopsy … as several thousand men in central Pennsylvania may have recently discovered! … READ MORE …

Does shift work really increase risk for clinically significant prostate cancer?

So the longer we go on using the PSA test as a primary tool for the assessment of risk for prostate cancer, the more we learn about what the test results may — or more importantly may not — actually be telling us. … READ MORE …

PSA testing, life and health insurance, and full disclosure

Many readers of this blog quite certainly have strong opinions about the position of the American Cancer Society (ACS) on use of the PSA test in assessment of risk for prostate cancer. However, one does have to give credit where credit is due on a related matter. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers